Critical Outcome Technologies Inc. (“COTI” or the “Company”) (TSX Venture: COT; OTCQB: COTQF), a clinical stage biotechnology company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has commenced dosing women in the fourth cohort of its ongoing Phase 1 clinical trial of COTI-2 intended for the treatment of gynecological cancers. The objective of the fourth cohort is to continue to evaluate the safety and tolerability of COTI-2.
“We are pleased to report that the first two patients in cohort 4 have begun receiving COTI‐2 at a dosage level of 1.7 mg/kg, an increase from the 1.0 mg/kg level of cohort 3. We are further pleased to report that there were no significant adverse events attributed to treatment in any of the cohort 3 patients,” said Alison Silva, COTI’s President & CEO. “Preliminary clinical data is consistent with the low toxicity profile observed during preclinical studies. Accordingly, the independent Dose Escalation Committee granted a favourable opinion to move ahead with the fourth cohort of patients. We are pleased with the Committee’s recommendation and trial advancement to date.” More information about COTI‐2 and the ongoing clinical study is available on the Company website: http://criticaloutcome.com/coti‐2.
